Banner
Biotechnology

Amgen, Inc. (Nasdaq: AMGN) – FYE 12/2017 – OVER VALUED – The stock is currently trading above my most recent $36 fair value estimate – Please See Linked Worksheet
02/24/18


Cambrex Corporation (NYSE: CBM) – FYE 12/2018 – FAIRLY VALUED The stock is currently trading at levels above my most recent $27 initiate target, but below my most recent $45 baseline value estimate. Please See Linked PDF Worksheet
Posted on 03/11/19


Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) – FYE 12/2017 – OVER VALUED – The stock is currently trading at levels above my most recent $157 fair value estimate – Please See Linked Worksheet
02/11/18


Gilead Sciences, Inc. (Nasdaq: GILD) – FYE 12/2017 – OVER VALUED The stock is currently trading at levels above my most recent $51 close target. Please See Linked PDF Worksheet
Posted on 07/22/18

Please note that worksheets are updated basis the most current SEC 10-K ANNUAL filing.